Exploring the Spectrum of Long Non-Coding RNA CARMN in Physiological and Pathological Contexts
Hui Li,
Chuannan Sun,
Bin Luo,
Chuzhi Zhan,
Weitao Li,
Lu Deng,
Kang Kang,
Deming Gou
Affiliations
Hui Li
Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518060, China
Chuannan Sun
Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518060, China
Bin Luo
Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518060, China
Chuzhi Zhan
Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518060, China
Weitao Li
Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518060, China
Lu Deng
Shenzhen Key Laboratory of Microbial Genetic Engineering, Vascular Disease Research Center, College of Life Sciences and Oceanography, Guangdong Provincial Key Laboratory of Regional Immunity and Disease, Carson International Cancer Center, School of Medicine, Shenzhen University, Shenzhen 518060, China
Kang Kang
Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518060, China
Deming Gou
Shenzhen Key Laboratory of Microbial Genetic Engineering, Vascular Disease Research Center, College of Life Sciences and Oceanography, Guangdong Provincial Key Laboratory of Regional Immunity and Disease, Carson International Cancer Center, School of Medicine, Shenzhen University, Shenzhen 518060, China
Cardiac mesoderm enhancer-associated non-coding RNA (CARMN), an evolutionarily conserved long non-coding RNA (lncRNA), serves as the host gene for the miR143/145 cluster. It plays a crucial role in cardiovascular cell differentiation and the maintenance of vascular smooth muscle cell (VSMC) homeostasis, which are vital for normal physiological processes. Specifically, CARMN is associated with the pathological progression of cardiovascular diseases such as atherosclerosis, abdominal aortic aneurysm, and chronic heart failure. Moreover, it acts as a tumor suppressor in various cancers, including hepatocellular carcinoma, bladder cancer, and breast cancer, highlighting its potential as a beneficial biomarker and therapeutic target. This review provides a detailed examination of the roles of CARMN, its evolutionary conservation, expression patterns, and regulatory mechanisms. It also outlines its significant implications in the diagnosis, prognosis, and treatment of these diseases, underscoring the need for further translational research to exploit its clinical potential.
